Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY) and Amneal Pharmaceuticals Inc (AMRX).
Alnylam Pharma (ALNY)
Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma on August 6 and set a price target of $125. The company’s shares closed yesterday at $80.50.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 19.4% and a 50.0% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Crispr Therapeutics AG, and Meiragtx Holdings Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $114.17 average price target, representing a 41.8% upside. In a report issued on August 6, Cowen & Co. also maintained a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
Amneal Pharmaceuticals Inc (AMRX)
Barclays analyst Balaji Prasad maintained a Hold rating on Amneal Pharmaceuticals Inc on August 6 and set a price target of $4. The company’s shares closed yesterday at $2.91, close to its 52-week low of $2.78.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of -0.8% and a 52.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Osmotica Pharmaceuticals Plc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amneal Pharmaceuticals Inc with a $12.40 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMRX:
